Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Abivax S.A.NASDAQ: ABVX

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables falls 15.7% from a year ago

Net receivables stood at €12.42M at the end of Q2 FY2026, down 15.7% from a year earlier. Over 3 fiscal years it compounded at +8.1% a year.

Context

  • Net receivables amounted to 2.7% of total assets at the end of Q2 FY2026, down 9.6 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -15.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€12.42M— QoQ
Last fiscal yearDec 2025
€10.49M-33.0% YoY
Year agoJun 2025
€14.74M-15.7% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.7%——
1 year-33.0%——
3-year CAGR+8.1%——
5-year CAGR——
10-year CAGR——

Net Receivables history

EUR · from the balance sheet

Latest · FY2025
10.49M EUR
Year-over-year change
-33.0%
4-year CAGR
+5.9%

Net Receivables vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -15.7% is the 5th highest of 6, against a peer median of +80.0%.
  • Net receivables amounts to 2.7% of total assets for ABVX, versus a peer median of 2.0%.
ABVX Competitors
Net Receivables for ABVX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$60.69M USD+182.5%+158.8%12.8%
RCUSArcus Biosciences, Inc.Jun 2026$36M USD+80.0%-28.1%3.9%
ANABAnaptysBio, Inc.Mar 2026$25.75M USD+44.0%+187.9%7.8%
NRIXNurix Therapeutics, Inc.Aug 2026$20M USD——1.7%
ABVXAbivax S.A.Jun 2026€12.42M EUR-15.7%+8.1%2.7%
IVAInventiva S.A.Dec 2025€9.12M EUR-25.0%+219.7%3.7%
ACRSAclaris Therapeutics, Inc.Mar 2026$4.81M USD+1825.6%+125.7%2.4%
SYRESpyre Therapeutics, Inc.Sep 2026$0 USD——0.0%
IMMXImmix Biopharma, Inc.Mar 2026$0 USD——0.0%
ANNXAnnexon, Inc.Mar 2026$0 USD——0.0%
AVTXAvalo Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding ABVX) —+80.0%+158.8%2.0%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.7M26.95M251.94M144.22M516.47M
Short-term Investments6K09.05M013.69M
Net Receivables8.34M8.32M19.1M15.66M10.49M
Inventory4M0000
Other Current Assets00(1K)00
Total Current Assets75.21M36.18M285.97M170.67M551.01M
Property, Plant & Equipment (Net)93K1.59M877K2.67M2.09M
Goodwill32.75M18.42M18.42M18.42M18.41M
Intangible Assets(647K)6.61M6.6M6.61M6.6M
Long-term Investments214K0124K126K0
Tax Assets00000
Other Non-current Assets2.75M12.75M15.07M6.74M5.98M
Total Non-current Assets35.15M39.36M41.09M34.56M33.08M
Total Assets109.23M75.54M327.06M205.23M584.09M
Account Payables18.56M15.48M47.22M43.82M37.55M
Short-term Debt10.06M29.49M30.88M42.84M28.46M
Tax Payables88K86K2.38M4.71M0
Deferred Revenue162K133K52K00
Other Current Liabilities(385K)2.87M3.51M532K(15.91M)
Total Current Liabilities32.26M51.46M88.12M92.83M62.99M
Long-term Debt40.27M8.29M26.62M52.16M30.22M
Deferred Tax Liabilities00005.85M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities10.37M7.77M16.15M18.22M29.46M
Total Non-current Liabilities51.03M16.89M42.94M71.81M66.09M
Total Liabilities83.3M68.36M131.05M164.64M129.08M
Common Stock168K223K629K633K784.67K
Retained Earnings(81.81M)(143.51M)(282.95M)(438.88M)(738.17M)
Accumulated OCI1K302.03K112K(75K)2.31M
Other Stockholders Equity00000
Minority Interest00000
Total Equity25.93M7.19M196.01M40.58M455.01M
Total Debt51.65M39.16M58.04M97.36M45.89M
Net Debt(9.05M)12.21M(193.9M)(46.86M)(470.58M)

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.